Beranda › Osteosarkoma › Alabama
Uji klinis Osteosarkoma di Alabama
7 studi untuk Osteosarkoma mencari peserta di lokasi di Alabama.
Kota di Alabama
Teks studi resmi (Bahasa Inggris)
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- University of Alabama/Children's of Alabama, Birmingham
Menerima pesertaFase 1/2
Hingga usia 26 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- University of Alabama/Children's of Alabama, Birmingham
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Children's Hospital of Alabama, Birmingham
Menerima pesertaFase 3
Hingga usia 50 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05235165Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital of Alabama, Birmingham
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT01790152Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Apr 2026 · NCT05297734A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital of Alabama/UAB, Birmingham
Menerima pesertaFase 2
18 Months – 40 Years · Semua jenis kelamin · Diperbarui 12 Agu 2025 · NCT05135975Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.